(4-((4-formylphenoxy)methyl)phenyl)boronic acid | 1229652-28-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: (4-((4-formylphenoxy)methyl)phenyl)boronic acid
• 英文别名: [4-[(4-Formylphenoxy)methyl]phenyl]boronic acid
• CAS: 1229652-28-1
• 化学式: C₁₄H₁₃BO₄
• 分子量: 256.066
• InChiKey: LJCBZNKURKWSBC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.76
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (4-((4-formylphenoxy)methyl)phenyl)boronic acid 在 哌啶 、 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 22.0h， 生成 (4-((4-((3-(4-fluorobenzyl)-2,4-dioxothiazolidin-5-yl)methyl)phenoxy)methyl)phenyl)boronic acid
  参考文献：
  名称：

  Structure-Based Design of Novel Boronic Acid-Based Inhibitors of Autotaxin

  摘要：

  Autotaxin (ATX) is a secreted phosphodiesterase that hydrolyzes the abundant phospholipid lysophosphatidylcholine (LPC) to produce lysophosphatidic acid (LPA). The ATX-LPA signaling axis has been implicated in inflammation, fibrosis, and tumor progression, rendering ATX an attractive drug target. We recently described a boronic add-based inhibitor of ATX, named HA155 (1). Here, we report the design of new inhibitors based on the crystal structure of ATX in complex with inhibitor 1. Furthermore, we describe the syntheses and activities of these new inhibitors, whose potencies can be explained by structural data. To understand the difference in activity between two different isomers with nanomolar potencies, we performed molecular docking experiments. Intriguingly, molecular docking suggested a remarkable binding pose for one of the isomers, which differs from the original binding pose of inhibitor 1 for ATX, opening further options for inhibitor design.

  DOI：

  10.1021/jm200310q
• 作为产物：
  描述：

  对溴溴苄 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 sodium periodate 、 potassium acetate 、 potassium hydroxide 作用下， 以 四氢呋喃 、 水 、 二甲基亚砜 为溶剂， 反应 23.5h， 生成 (4-((4-formylphenoxy)methyl)phenyl)boronic acid
  参考文献：
  名称：

  Structure-Based Design of Novel Boronic Acid-Based Inhibitors of Autotaxin

  摘要：

  Autotaxin (ATX) is a secreted phosphodiesterase that hydrolyzes the abundant phospholipid lysophosphatidylcholine (LPC) to produce lysophosphatidic acid (LPA). The ATX-LPA signaling axis has been implicated in inflammation, fibrosis, and tumor progression, rendering ATX an attractive drug target. We recently described a boronic add-based inhibitor of ATX, named HA155 (1). Here, we report the design of new inhibitors based on the crystal structure of ATX in complex with inhibitor 1. Furthermore, we describe the syntheses and activities of these new inhibitors, whose potencies can be explained by structural data. To understand the difference in activity between two different isomers with nanomolar potencies, we performed molecular docking experiments. Intriguingly, molecular docking suggested a remarkable binding pose for one of the isomers, which differs from the original binding pose of inhibitor 1 for ATX, opening further options for inhibitor design.

  DOI：

  10.1021/jm200310q

文献信息

• Design, synthesis and biological evaluation of imidazolidine-2,4-dione and 2-thioxothiazolidin-4-one derivatives as lymphoid-specific tyrosine phosphatase inhibitors
  作者：Xiao Liang、Huansheng Fu、Peng Xiao、Hao Fang、Xuben Hou

  DOI：10.1016/j.bioorg.2020.104124

  日期：2020.10

  Lymphoid-specific tyrosine phosphatase (LYP), which exclusively exists in immune cells and down-regulates T cell receptor signaling (TCR), has becoming a potent target for various autoimmune diseases. Herein, we designed and synthesized imidazolidine-2,4-dione and 2-thioxothiazolidin-4-one derivatives as new LYP inhibitors. Among them, the cinnamic acids-based inhibitors (9p and 9r) displayed good

  淋巴特异性酪氨酸磷酸酶（LYP）专门存在于免疫细胞中，并下调T细胞受体信号传导（TCR），已成为各种自身免疫疾病的有效靶标。在本文中，我们设计并合成了咪唑烷-2,4-二酮和2-硫代噻唑烷二-4-酮衍生物作为新的LYP抑制剂。其中，基于肉桂酸的抑制剂（9p和9r）表现出良好的LYP抑制活性（IC 50  = 2.85–6.95μM）。特别是，最有效的抑制剂9r被鉴定为竞争性抑制剂（K i  = 1.09μM），可逆地结合LYP。同时，与已知的LYP抑制剂A15相比，9r对其他磷酸酶的选择性更好。此外，化合物9r可以调节Jurkat T细胞中TCR相关的信号传导途径。
• Discovery of Novel Boron-Containing N-Substituted Oseltamivir Derivatives as Anti-Influenza A Virus Agents for Overcoming N1-H274Y Oseltamivir-Resistant
  作者：Ruifang Jia、Jiwei Zhang、Jian Zhang、Chiara Bertagnin、Anna Bonomini、Laura Guizzo、Zhen Gao、Xiangkai Ji、Zhuo Li、Chuanfeng Liu、Han Ju、Xiuli Ma、Arianna Loregian、Bing Huang、Peng Zhan、Xinyong Liu

  DOI：10.3390/molecules27196426

  日期：——

  To address drug resistance to influenza virus neuraminidase inhibitors (NAIs), a series of novel boron-containing N-substituted oseltamivir derivatives were designed and synthesized to target the 150-cavity of neuraminidase (NA). In NA inhibitory assays, it was found that most of the new compounds exhibited moderate inhibitory potency against the wild-type NAs. Among them, compound 2c bearing 4-(3-boronic acid benzyloxy)benzyl group displayed weaker or slightly improved activities against group-1 NAs (H1N1, H5N1, H5N8 and H5N1-H274Y) compared to that of oseltamivir carboxylate (OSC). Encouragingly, 2c showed 4.6 times greater activity than OSC toward H5N1-H274Y NA. Moreover, 2c exerted equivalent or more potent antiviral activities than OSC against H1N1, H5N1 and H5N8. Additionally, 2c demonstrated low cytotoxicity in vitro and no acute toxicity at the dose of 1000 mg/kg in mice. Molecular docking of 2c was employed to provide a possible explanation for the improved anti-H274Y NA activity, which may be due to the formation of key additional hydrogen bonds with surrounding amino acid residues, such as Arg152, Gln136 and Val149. Taken together, 2c appeared to be a promising lead compound for further optimization.

  为了解决流感病毒神经氨酸酶抑制剂（NAIs）的耐药性问题，设计并合成了一系列新型含硼N-取代奥司他韦衍生物，以针对神经氨酸酶（NA）的150-腔。在NA抑制实验中发现，大多数新化合物对野生型NA表现出中等的抑制效力。其中，带有4-（3-硼酸苄氧基）苯基基团的2c化合物在对组1 NA（H1N1，H5N1，H5N8和H5N1-H274Y）的抑制活性方面显示出比奥司他韦羧酸盐（OSC）更弱或略有改善。令人鼓舞的是，2c对H5N1-H274Y NA的活性比OSC高出4.6倍。此外，2c对H1N1，H5N1和H5N8的抗病毒活性相当或更强于OSC。此外，2c在体外表现出低细胞毒性，在小鼠1000 mg / kg的剂量下没有急性毒性。采用2c的分子对接来解释其改善的抗H274Y NA活性的可能原因，这可能是由于与周围氨基酸残基（如Arg152，Gln136和Val149）形成关键的额外氢键。综上所述，2c似乎是进一步优化的有前途的先导化合物。
• 一种铱配合物探针及其制备方法和应用
  申请人：兰州大学

  公开号：CN115505008A

  公开（公告）日：2022-12-23

  本发明公开了一种铱配合物探针及其制备方法和应用，属于探针技术领域。该铱配合物探针由金属中心、环金属配体和含有苯硼酸结构的辅助配体组成，结构如下所示： 该铱配合物在检测pH值过程中荧光发射波长不发生变化，随pH值逐渐降低，发光强度逐渐增强，在酸性、中性以及碱性条件下均具有很好的稳定性，并且具有良好的酸碱可逆性，所以可准确、灵敏的检测出环境pH值；与此同时，该铱配合物探针具有较低的细胞毒性和优异的线粒体靶向能力，能够精确抵达线粒体，所以还可以准确、灵敏的检测出细胞微环境pH值探针。该铱配合物探针的制备方法反应条件温和，制备过程简单，产率较高，具备大规模生产的条件。
• Discovery and Optimization of Boronic Acid Based Inhibitors of Autotaxin
  作者：Harald M. H. G. Albers、Laurens A. van Meeteren、David A. Egan、Erica W. van Tilburg、Wouter H. Moolenaar、Huib Ovaa

  DOI：10.1021/jm1005012

  日期：2010.7.8

  Autotaxin (ATX) is an extracellular enzyme that hydrolyzes lysophosphatidylcholine (LPC) to produce the lipid mediator lysophosphatidic acid (LPA). The ATX LPA signaling axis has been implicated in diverse physiological and pathological processes, including vascular development, inflammation, fibrotic disease, and tumor progression. Therefore targeting ATX with small molecule inhibitors is an attractive therapeutic strategy. We recently reported that 2,4-thiazolidinediones inhibit ATX activity in the micromolar range. Interestingly, inhibitory potency was dramatically increased by introduction of a boronic acid moiety, designed to target the active site threonine in ATX. Here we report on the discovery and further optimization of boronic acid based ATX inhibitors. The most potent of these compounds inhibits ATX-mediated LPC hydrolysis in the nanomolar range (IC50 = 6 nM). The finding that ATX can be targeted by boronic acids may aid the development of ATX inhibitors for therapeutic use.
• Structure-Based Design of Novel Boronic Acid-Based Inhibitors of Autotaxin
  作者：Harald M. H. G. Albers、Loes J. D. Hendrickx、Rob J. P. van Tol、Jens Hausmann、Anastassis Perrakis、Huib Ovaa

  DOI：10.1021/jm200310q

  日期：2011.7.14

  Autotaxin (ATX) is a secreted phosphodiesterase that hydrolyzes the abundant phospholipid lysophosphatidylcholine (LPC) to produce lysophosphatidic acid (LPA). The ATX-LPA signaling axis has been implicated in inflammation, fibrosis, and tumor progression, rendering ATX an attractive drug target. We recently described a boronic add-based inhibitor of ATX, named HA155 (1). Here, we report the design of new inhibitors based on the crystal structure of ATX in complex with inhibitor 1. Furthermore, we describe the syntheses and activities of these new inhibitors, whose potencies can be explained by structural data. To understand the difference in activity between two different isomers with nanomolar potencies, we performed molecular docking experiments. Intriguingly, molecular docking suggested a remarkable binding pose for one of the isomers, which differs from the original binding pose of inhibitor 1 for ATX, opening further options for inhibitor design.